News | March 20, 2024
AstraZeneca buys biopharmaceutical company Fusion
To accelerate the development of next-generation radioconjugates to treat cancer
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
A five-day inspection was concluded successfully with no critical and no major observations raised
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Additional capacity broadens Grace’s fine chemical capabilities for API production
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Mungara has over 25+ years of experience in the supply chain domain
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Subscribe To Our Newsletter & Stay Updated
